secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001193125-25-068789
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Atara CFO/COO Eric Hyllengren to depart March 31; Yanina Grant-Huerta named CAO
-------------------------------------------------------------------------------

- CFO/COO Eric Hyllengren's employment ends March 31, 2025; he will provide consulting through July 31 at an hourly rate.
- Hyllengren receives severance including 2024 bonus; he relinquishes all vested and unvested stock option awards.
- Yanina Grant-Huerta appointed Chief Accounting Officer and principal accounting officer effective March 31; she was VP of FP&A since March 2023.
- Grant-Huerta previously spent 13 years at Amgen; no family relationships or related-party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525068789/0001193125-25-068789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525068789/d905889d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-068789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer